PD-1 gene-deleted autologous T cells

PD-1 gene-deleted autologous T cells are an experimental cell therapy involving the ex vivo genetic modification of a patient's own T lymphocytes to eliminate the expression of the Programmed Cell Death Protein 1 (PD-1) receptor. By using gene-editing technologies such as CRISPR/Cas9 to knock out the PDCD1 gene, these T cells are rendered resistant to PD-L1-mediated inhibition within the tumor microenvironment, potentially enhancing their anti-tumor effector functions. This approach is being investigated by Zhejiang Provincial People's Hospital for the treatment of advanced lung cancer, particularly in patients with high PD-L1 expression, microsatellite instability-high (MSI-H), or high tumor mutational burden (TMB).

Other names

PD-1 knockout T cellsPD1 knockout T cellsPD 1 knockout T cellsPD-1 deleted T cellsPD1 deleted T cellsPD 1 deleted T cellsautologous PD-1 gene-deleted T lymphocytes